Endomorphin 1 acetate,一种高度选择性的,高亲和力的μ-opioid受体激动剂 (Ki: 1.11 nM),对 kappa3结合位点具有高亲和力,Ki值为 20 到 30 nM 之间。Endomorphin 1 acetate 具有镇痛特性。
生物活性 | Endomorphin 1 acetate, a high affinity, highly selective agonist of theμ-opioid receptor(Ki: 1.11 nM), displays reasonable affinities for kappa3binding sites, withKivalue between 20 and 30 nM. Endomorphin 1 acetate has antinociceptive properties[1][2][4]. |
IC50& Target[1] | μ Opioid Receptor/MOR 1.11 nM (Ki) |
|
体外研究 (In Vitro) | Endomorphin 1 acetate inhibitsForskolin(HY-15371) (1 μM) stimulated cyclic AMP formation with a pIC50value of 8.03 in In CHOμ cells[5]. Endomorphin 1 (1-10 μM) acetate increases interleukin-8 secretion in Caco-2 cells[6]. Endomorphin 1 (1 μM) acetate inhibits excitatory transmission in adult rat substantia gelatinosa neurons[7].
|
体内研究 (In Vivo) | Endomorphin 1 (i.c.v.) acetate shows antinociceptive properties in mice, with an ED50value of 6.16 nM[2]. Endomorphin 1 (50 μg/kg, i.v., rats) acetate alleviates myocardial ischemia/reperfusion injury (MIRI) by inhibiting the inflammatory response[3].
Animal Model: | ICR mice[2]. | Dosage: | 6.16 nM (ED50) | Administration: | Intracerebroventricularly (i.c.v.) injection | Result: | Inhibited dose-dependently the tail-flick response. |
Animal Model: | Rats[3].
| Dosage: | 50 μg/kg | Administration: | Intravenously following LAD ligation for 25 min, subsequently the LAD was reperfused for 120 min. | Result: | Alleviated MIRI by reducing the production of free radicals. Dncreased LDH and CK-MB activities. Increased SOD activity and decreased MDA content. Decreased IL-6 and TNF-α plasma content. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Sealed storage, away from moisture and light, under nitrogen Powder | -80°C | 2 years | | -20°C | 1 year |
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |
溶解性数据 | In Vitro: DMSO : 125 mg/mL(186.36 mM;Need ultrasonic) 配制储备液 1 mM | 1.4909 mL | 7.4543 mL | 14.9087 mL | 5 mM | 0.2982 mL | 1.4909 mL | 2.9817 mL | 10 mM | 0.1491 mL | 0.7454 mL | 1.4909 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (3.10 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.10 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (3.10 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.10 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (3.10 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.10 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|